RxDoctor Payments Data

Joseph Corning, MD

Cardiovascular Disease · Middletown, CTNPI 1669580569

Payments from drug & device makers

$1,211in general payments, 2019–2025

Across 60 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$227
  • Boston Scientific$161
  • Pfizer$115
  • Novartis$90
  • Regeneron Healthcare Solutions, Inc.$75
  • Medtronic$72
  • plus $471 from 13 others

What the payments were for

  • Food & beverage$1,18998%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,211 in reported general payments places this provider in the 45th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$220,762
Medicare patients
1,240
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban689$848,608
XareltoRivaroxaban65$93,126
EntrestoSacubitril/Valsartan63$76,477
JardianceEmpagliflozin24$21,336
BrilintaTicagrelor26$19,460
Repatha SureclickEvolocumab16$13,224
Metoprolol Succinate552$8,722
Dabigatran EtexilateDabigatran Etexilate Mesylate23$7,524
Diltiazem 24hr Er (Cd)Diltiazem Hcl204$5,514
Rosuvastatin Calcium358$5,282
BystolicNebivolol Hcl15$5,145
Valsartan154$3,534
Prasugrel Hcl19$3,520
Atorvastatin Calcium352$3,468
Nebivolol Hcl58$3,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$848,608689 claims
NovartisEntresto$90$76,47763 claims
Boehringer IngelheimJardiance$52$21,33624 claims
AstraZenecaBrilinta$57$19,46026 claims
Kowa Pharmaceuticals America, Inc.Bystolic$12$5,14515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →